AHRQ Alzheimer's Diagnosis Technology Assessment To Focus On PET
This article was originally published in The Gray Sheet
Executive Summary
The Agency for Healthcare Research & Quality's technology assessment on Alzheimer's disease diagnosis should include a systematic review of positron emission tomography studies as well as literature citations for other imaging modalities, according to the Medicare Coverage Advisory Commission's executive committee.
You may also be interested in...
MCAC Panel Will Review PET Coverage For Dementia, Alzheimer’s Disease
A technology assessment finding insufficient evidence to support coverage of FDG-PET for diagnosis and patient management of Alzheimer's disease and dementia will be weighed by the Medicare Coverage Advisory Commission Diagnostic Imaging Panel in Baltimore Jan. 10
MCAC Panel Will Review PET Coverage For Dementia, Alzheimer’s Disease
A technology assessment finding insufficient evidence to support coverage of FDG-PET for diagnosis and patient management of Alzheimer's disease and dementia will be weighed by the Medicare Coverage Advisory Commission Diagnostic Imaging Panel in Baltimore Jan. 10
PET Technology Review For Alzheimer's To Look At Prognostic Benefits
HCFA's review of positron emission tomography imaging for Alzheimer's should take into account psycho-social benefits of the procedure in addition to its diagnostic capability, according to the executive committee (EC) of the Medicare Coverage Advisory Committee.